Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q3 FY2020 Earnings Presentation
18 slides from Alkem Laboratories's earnings presentation, Feb 7, 2020
Slide 1: Cover letter to stock exchanges
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office: ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 7th February, 2020 The Corpo
Slide 2: Press Release: Alkem reports Q3FY20 and 9MFY20 Results
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91 -22-3982 9999 • Fax: 022-2495 2955 • Email : contact@alkem.com • Website: www.alkemlabs.com • GIN: L00305MH1973PLC174201 Press Release Alkem repor
Slide 3: Operational Highlights: India Business
<8> ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West) , Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 ALKEM • Email: contact@alkem.com • Website: www.alkemlabs.com • GIN: L00305MH1973PLC174201 Operational Highlights Ind
Slide 4: Other International Markets and R&D Investments
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Parel (West), Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 • Other International Marke
Slide 5: Q3FY20 and 9MFY20 Conference Call
<a> ALKEM ALKEM LABORATORIES LTD. Regd. Office : ALKEM HOUSE, Senapati Bapat Marg, Lower Pare! (West) , Mumbai - 400 013, Maharashtra, India. • Phone: +91-22-3982 9999 • Fax: 022-2495 2955 • Email: contact@alkem.com • Website: www.alkemlabs.com • CIN: L00305MH1973PLC174201 Q3FV20 and 9MFV20 Conferen
Slide 6: Investor Presentation Q3FY20
........ <a> ALKEM Alkem Laboratories Limited Investor Presentation Q3FY20 February 7, 2020
Slide 7: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 8: Key Highlights of Q3FY20 and 9MFY20
Key Highlights of Q3FY20 and 9MFY20 Strong quarter marked by healthy revenue growth and significant improvement in EBITDA margins • Revenue from Operations grew by 13.3% YoY during the quarter, accompanied by 450 bps YoY improvement in EBITDA margin • Profit After Tax for the quarter grew by 88.6% c
Slide 9: Key Financial Highlights – Q3FY20
Key Financial Highlights – Q3FY20 All figures in Rs mn Revenue from Operations India sales 14,239 12,475 21,818 19,263 Q3FY19 Q3FY20 International sales 7,253 6,532 Q3FY19 Q3FY20 Q3FY19 Q3FY20
Slide 10: Key Financial Highlights – Q3FY20
Key Financial Highlights – Q3FY20 All figures in Rs mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 4,533 13,474 11,283 3,135 58.6% 61.8% 16.3% 20.8% Q3FY19 Q3FY20 Q3FY19 Q3FY20 PBT (before Minority Interest) PAT (after Minority Interest) 3,820 4,046 2,581 2,025 Q3FY19 Q3FY20 Q3FY19 Q3FY20
Slide 11: Key Financial Highlights 9MFY20 (Consolidated)
Key Financial Highlights 9MFY20 (Consolidated) Particulars (Rs mn) 9MFY20 9MFY19 YoY growth Revenue from Operations 62,954 55,042 14.4% Gross Profit 38,448 33,348 15.3% Gross Profit margin 61.1% 60.6% EBITDA 11,704 8,809 32.9% EBITDA margin 18.6% 16.0% PBT 10,245 7,559 35.5% PBT margin 16.3% 13.7% P
Slide 12: India Business
India Business India Business: Q3FY20 Sales of Rs.14,239 million (14.1% YoY growth) • India sales contributed 66.3% to total sales in Q3FY20 • In Q3FY20, Company’s secondary sales grew by 15.4% YoY - significantly ahead of the IPM growth of 9.6% YoY. Similarly in 9MFY20 also, the Company grew ahead
Slide 13: Secondary Sales Performance
Secondary Sales Performance Outperformance across most of the major therapeutic areas in Q3FY20 +1 Established therapeutic Market rank 1 3 3 4 areas of Alkem 20.8% 17.3% 12.1% 8.4% 9.7% 7.6% 7.0% 7.3% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growt
Slide 14: US Business
US Business US Business: Q3FY20 Sales of Rs.5,837 million (12.6% growth YoY) • US sales contributed 27.2% to total sales in Q3FY20 • The YoY growth in the US business during the quarter was mainly driven by new product launches • In Q3FY20, the Company filed 4 ANDAs with the US FDA and received 4 ap
Slide 15: Update on the US FDA inspection
Update on the US FDA inspection Facility Scope Last inspection Status post last inspection St. Louis (US) Formulation February 2020 Received Form 483 with 3 observations Daman (India) Formulation August 2019 EIR# received in October 2019, thereby successfully closing the inspection Baddi (India) For
Slide 16: Other International Business
Other International Business Other International Business: Q3FY20 Sales of Rs.1,416 million (5.0% growth YoY) • Other International Market sales contributed 6.6% to total sales in Q3FY20 • The Company has presence in Australia, Europe, South East Asia, Latin America and Africa • Company’s key market
Slide 17: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on December 31, 2019 Non-Institution, 19.24% Institution, 14.72% Promoter & Promoter Group, 66.04% Institution – Mutual Funds, Alternate Investment Funds, Foreign Portfolio Investors, Financial Institutions / Banks Non-Institution – Public, Other B
Slide 18: Thank You
Thank You <8> ALKEM